8 Bibliografia
Alcami, A. and U. H. Koszinowski (2000). "Viral mechanisms of immune evasion." Trends Microbiol 8(9): 410-8.
Alisky, J. M., S. M. Hughes, et al. (2000). "Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors." Neuroreport 11(12): 2669-73.
Amara, R. R., F. Villinger, et al. (2002). "Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine." Vaccine 20(15): 1949-55.
Andersen, H., D. Dempsey, et al. (2000). "Expression of intracellular IFN-gamma in HSV-1- specific CD8+ T cells identifies distinct responding subpopulations during the primary response to infection." J Immunol 165(4): 2101-7.
Anderson, B. J. (2008). "Managing herpes gladiatorum outbreaks in competitive wrestling:
the 2007 Minnesota experience." Curr Sports Med Rep 7(6): 323-7.
Arduino, P. G. and S. R. Porter (2008). "Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features." J Oral Pathol Med 37(2): 107-21.
Arii, J., H. Goto, et al. (2010) "Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1." Nature 467(7317): 859-62.
Ashley, R. L. and A. Wald (1999). "Genital herpes: review of the epidemic and potential use of type-specific serology." Clin Microbiol Rev 12(1): 1-8.
Barker, N. H. (2008). "Ocular herpes simplex." Clin Evid (Online) 2008.
Barouch, D. H., S. Santra, et al. (2001). "Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination." J Virol 75(11): 5151-8.
Barraza, R. A., C. A. Rasmussen, et al. (2009). "Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates." Hum Gene Ther 20(3): 191-200.
Basten, A. and B. Fazekas de St Groth (2008). "Special regulatory T-cell review: T-cell dependent suppression revisited." Immunology 123(1): 33-9.
Beauman, J. G. (2005). "Genital herpes: a review." Am Fam Physician 72(8): 1527-34.
Brady, R. C. and D. I. Bernstein (2004). "Treatment of herpes simplex virus infections."
Antiviral Res 61(2): 73-81.
Breckpot, K., J. L. Aerts, et al. (2007). "Lentiviral vectors for cancer immunotherapy:
transforming infectious particles into therapeutics." Gene Ther 14(11): 847-62.
Brockman, M. A. and D. M. Knipe (2008). "Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection." Vaccine 26 Suppl 8: I94-9.
Brooks, A. I., C. S. Stein, et al. (2002). "Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors." Proc Natl Acad Sci U S A 99(9): 6216-21.
Brown, J. C. (2007). "High G+C Content of Herpes Simplex Virus DNA: Proposed Role in Protection Against Retrotransposon Insertion." Open Biochem J 1: 33-42.
Buxbaum, S., M. Geers, et al. (2003). "Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed?" Med Microbiol Immunol 192(3): 177-81.
Cattamanchi, A., C. M. Posavad, et al. (2008). "Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle- free injection system." Clin Vaccine Immunol 15(11): 1638-43.
Celum, C., A. Wald, et al. (2010) "Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2." N Engl J Med 362(5): 427-39.
Chakrabarty, A., K. R. Pang, et al. (2004). "Emerging therapies for herpes viral infections (types 1 - 8)." Expert Opin Emerg Drugs 9(2): 237-56.
Connolly, J. B. (2002). "Lentiviruses in gene therapy clinical research." Gene Ther 9(24):
1730-4.
Corey, L., A. G. Langenberg, et al. (1999). "Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group." Jama 282(4): 331-40.
Corey, L. and A. Wald (2009). "Maternal and neonatal herpes simplex virus infections." N Engl J Med 361(14): 1376-85.
Corey, L., A. Wald, et al. (2004). "The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics." J Acquir Immune Defic Syndr 35(5): 435-45.
Coyle, P. V., A. Desai, et al. (1999). "A comparison of virus isolation, indirect
primary and recurrent herpes simplex type 1 and type 2 infections." J Virol Methods 83(1- 2): 75-82.
Decman, V., M. L. Freeman, et al. (2005). "Immune control of HSV-1 latency." Viral Immunol 18(3): 466-73.
Deshpande, S. P., U. Kumaraguru, et al. (2000). "Why do we lack an effective vaccine against herpes simplex virus infections?" Microbes Infect 2(8): 973-8.
Di Lullo, G., E. Soprana, et al. (2009). "Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection." J Virol Methods 156(1-2): 37-43.
Divito, S., T. L. Cherpes, et al. (2006). "A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency." Immunol Res 36(1-3): 119-26.
Dobbs, M. E., J. E. Strasser, et al. (2005). "Clearance of herpes simplex virus type 2 by CD8+
T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms." J Virol 79(23): 14546-54.
Dolan, A., F. E. Jamieson, et al. (1998). "The genome sequence of herpes simplex virus type 2." J Virol 72(3): 2010-21.
Drape, R. J., M. D. Macklin, et al. (2006). "Epidermal DNA vaccine for influenza is immunogenic in humans." Vaccine 24(21): 4475-81.
Emmert, D. H. (2000). "Treatment of common cutaneous herpes simplex virus infections."
Am Fam Physician 61(6): 1697-706, 1708.
Esmann, J. (2001). "The many challenges of facial herpes simplex virus infection." J Antimicrob Chemother 47 Suppl T1: 17-27.
Fatahzadeh, M. and R. A. Schwartz (2007). "Human herpes simplex virus infections:
epidemiology, pathogenesis, symptomatology, diagnosis, and management." J Am Acad Dermatol 57(5): 737-63; quiz 764-6.
Fillet, A. M. (2002). "Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients." Drugs Aging 19(5): 343-54.
Flotte, T. R., P. Ng, et al. (2007). "Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis." Mol Ther 15(2): 229-41.
Fotouhi, F., H. Soleimanjahi, et al. (2008). "Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting." FEMS Immunol Med Microbiol 54(1): 18-26.
Freeman, E. E., H. A. Weiss, et al. (2006). "Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies." Aids 20(1): 73-83.
Friedmann, T. and J. K. Yee (1995). "Pseudotyped retroviral vectors for studies of human gene therapy." Nat Med 1(3): 275-7.
Gianni, T., M. Amasio, et al. (2009). "Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain." J Biol Chem 284(26): 17370-82.
Gianni, T., P. L. Martelli, et al. (2005). "The ectodomain of herpes simplex virus glycoprotein H contains a membrane alpha-helix with attributes of an internal fusion peptide, positionally conserved in the herpesviridae family." J Virol 79(5): 2931-40.
Glick, M. (2002). "Clinical aspects of recurrent oral herpes simplex virus infection."
Compend Contin Educ Dent 23(7 Suppl 2): 4-8.
Graham, F. L., J. Smiley, et al. (1977). "Characteristics of a human cell line transformed by DNA from human adenovirus type 5." J Gen Virol 36(1): 59-74.
Gupta, R., T. Warren, et al. (2007). "Genital herpes." Lancet 370(9605): 2127-37.
Heineman, T. C., L. Pesnicak, et al. (2004). "Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge." Vaccine 22(20): 2558- 65.
Heldwein, E. E., H. Lou, et al. (2006). "Crystal structure of glycoprotein B from herpes simplex virus 1." Science 313(5784): 217-20.
Higaki, S., B. M. Gebhardt, et al. (2002). "Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion." Invest Ophthalmol Vis Sci 43(6):
1862-9.
Howe, S. J., M. R. Mansour, et al. (2008). "Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients." J Clin Invest 118(9): 3143-50.
Iijima, N., M. M. Linehan, et al. (2008). "Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus." J Exp Med 205(13): 3041-52.
Johnson, A. J., C. F. Chu, et al. (2008). "Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords." J Virol 82(19): 9678-88.
Johnson, D. C. (1991). "Adenovirus vectors as potential vaccines against herpes simplex virus." Rev Infect Dis 13 Suppl 11: S912-6.
Johnston, J. C., M. Gasmi, et al. (1999). "Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors." J Virol 73(6):
4991-5000.
Kawai, T. and S. Akira (2006). "Innate immune recognition of viral infection." Nat Immunol 7(2): 131-7.
Koelle, D. M., H. Abbo, et al. (1994). "Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions." J Infect Dis 169(5): 956-61.
Krawczyk, A., J. Krauss, et al. (2011) "Impact of Valency of a Glycoprotein B Specific Monoclonal Antibody on Neutralization of Herpes Simplex Virus." J Virol.
Krummenacher, C., V. M. Supekar, et al. (2005). "Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry." Embo J 24(23): 4144-53.
Kumaraguru, U. and B. T. Rouse (2000). "Application of the intracellular gamma interferon assay to recalculate the potency of CD8(+) T-cell responses to herpes simplex virus." J Virol 74(12): 5709-11.
Kutzler, M. A. and D. B. Weiner (2008). "DNA vaccines: ready for prime time?" Nat Rev Genet 9(10): 776-88.
Lafferty, W. E. (2002). "The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing." Herpes 9(2): 51-5.
Lafferty, W. E., L. Downey, et al. (2000). "Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention." J Infect Dis 181(4): 1454-7.
Lanier, L. L. (2008). "Evolutionary struggles between NK cells and viruses." Nat Rev Immunol 8(4): 259-68.
Lin, Y. L., D. Noel, et al. (2004). "Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis." Hum Gene Ther 15(6): 588-96.
Liu, M. A., B. Wahren, et al. (2006). "DNA vaccines: recent developments and future possibilities." Hum Gene Ther 17(11): 1051-61.
Llano, M., N. Gaznick, et al. (2009). "Rapid, controlled and intensive lentiviral vector-based RNAi." Methods Mol Biol 485: 257-70.
Lund, J., A. Sato, et al. (2003). "Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells." J Exp Med 198(3): 513-20.
Luttge, B. G., M. Shehu-Xhilaga, et al. (2008). "Molecular characterization of feline immunodeficiency virus budding." J Virol 82(5): 2106-19.
Manavi, K., A. McMillan, et al. (2004). "Herpes simplex virus type 1 remains the principal cause of initial anogenital herpes in Edinburgh, Scotland." Sex Transm Dis 31(5): 322-4.
Mancini-Bourgine, M., H. Fontaine, et al. (2006). "Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers." Vaccine 24(21): 4482-9.
Mangeot, P. E., K. Duperrier, et al. (2002). "High levels of transduction of human dendritic cells with optimized SIV vectors." Mol Ther 5(3): 283-90.
Manning, W. C., X. Paliard, et al. (1997). "Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D." J Virol 71(10):
7960-2.
Marcus, B., J. Lipozencic, et al. (2005). "Herpes simplex: autoinoculation versus dissemination." Acta Dermatovenerol Croat 13(4): 237-41.
Martin, J. E., T. C. Pierson, et al. (2007). "A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial." J Infect Dis 196(12): 1732-40.
Mettenleiter, T. C., B. G. Klupp, et al. (2006). "Herpesvirus assembly: a tale of two membranes." Curr Opin Microbiol 9(4): 423-9.
Mettenleiter, T. C., B. G. Klupp, et al. (2009). "Herpesvirus assembly: an update." Virus Res 143(2): 222-34.
Mikloska, Z., P. P. Sanna, et al. (1999). "Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro." J Virol 73(7): 5934-44.
Milligan, G. N., K. L. Dudley-McClain, et al. (2004). "T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice." J Reprod Immunol 61(2): 115-27.
Miyoshi, H., U. Blomer, et al. (1998). "Development of a self-inactivating lentivirus vector."
J Virol 72(10): 8150-7.
Mossman, K. L., K. E. Taylor,et al. (2009). "Innate and adaptive immune responses to herpes simplex virus." Viruses 1(3): 979-1002.
Mueller, S. N., C. M. Jones, et al. (2002). "Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus." J Exp Med 195(5): 651-6.
Muller, W. J., C. A. Jones, et al. (2010) "Immunobiology of herpes simplex virus and cytomegalovirus infections of the fetus and newborn." Curr Immunol Rev 6(1): 38-55.
Naldini, L. (1996). "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector." Science 272: 263-267.
Nandakumar, S., S. N. Woolard, et al. (2008). "Natural killer cells as novel helpers in anti- herpes simplex virus immune response." J Virol 82(21): 10820-31.
Newcomb, W. W., F. P. Booy, et al. (2007). "Uncoating the herpes simplex virus genome." J Mol Biol 370(4): 633-42.
Ohana, B., M. Lipson, et al. (2000). "Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies." Clin Diagn Lab Immunol 7(6): 904-8.
Ouyang, W., J. K. Kolls, et al. (2008). "The biological functions of T helper 17 cell effector cytokines in inflammation." Immunity 28(4): 454-67.
Parry, C., S. Bell, et al. (2005). "Herpes simplex virus type 1 glycoprotein H binds to alphavbeta3 integrins." J Gen Virol 86(Pt 1): 7-10.
Pedersen, N. C., E. W. Ho, et al. (1987). "Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome." Science 235(4790): 790-3.
Pepose, J. S., T. L. Keadle, et al. (2006). "Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy." Am J Ophthalmol 141(3): 547-557.
Pincha, M., B. S. Sundarasetty, et al. (2010) "Lentiviral vectors for immunization: an inflammatory field." Expert Rev Vaccines 9(3): 309-21.
Pistello, M., L. Vannucci, et al. (2007). "Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes."
Genet Vaccines Ther 5: 8.
Poeschla, E. M., F. Wong-Staal, et al. (1998). "Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors." Nat Med 4(3): 354-7.
Price, M. A., S. S. Case, et al. (2002). "Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cells." Mol Ther 6(5):
645-52.
Puck, J. M. and H. L. Malech (2006). "Gene therapy for immune disorders: good news tempered by bad news." J Allergy Clin Immunol 117(4): 865-9.
Rajalakshmi, R., R. Kumari, et al. (2010) "Acyclovir versus valacyclovir." Indian J Dermatol Venereol Leprol 76(4): 439-44.
Ramachandran, S. and P. R. Kinchington (2007). "Potential prophylactic and therapeutic vaccines for HSV infections." Curr Pharm Des 13(19): 1965-73.
Reske, A., G. Pollara, et al. (2007). "Understanding HSV-1 entry glycoproteins." Rev Med Virol 17(3): 205-15.
Rudnick, C. M. and G. S. Hoekzema (2002). "Neonatal herpes simplex virus infections." Am Fam Physician 65(6): 1138-42.
Saenz, D. T. and E. M. Poeschla (2004). "FIV: from lentivirus to lentivector." J Gene Med 6 Suppl 1: S95-104.
Sauter, S. L. and M. Gasmi (2001). "FIV vector systems." Somat Cell Mol Genet 26(1-6): 99- 129.
Seppanen, M., S. Meri, et al. (2006). "Subtly impaired humoral immunity predisposes to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia." J Infect Dis 194(5): 571-8.
Sheridan, B. S., T. L. Cherpes, et al. (2009). "Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes." J Virol 83(5): 2237-45.
Siapati, E. K., B. W. Bigger, et al. (2005). "Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells." Mol Ther 12(3): 537-46.
Simmons, A. (2002). "Clinical manifestations and treatment considerations of herpes simplex virus infection." J Infect Dis 186 Suppl 1: S71-7.
Simpson-Holley, M., R. C. Colgrove, et al. (2005). "Identification and functional evaluation of cellular and viral factors involved in the alteration of nuclear architecture during herpes simplex virus 1 infection." J Virol 79(20): 12840-51.
Sinn, P. L., E. R. Burnight, et al. (2005). "Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer." J Virol 79(20): 12818- 27.
Sirven, A., F. Pflumio, et al. (2000). "The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells." Blood 96(13): 4103-10.
Sodeik, B. (2000). "Mechanisms of viral transport in the cytoplasm." Trends Microbiol 8(10): 465-72.
Spear, P. G. and R. Longnecker (2003). "Herpesvirus entry: an update." J Virol 77(19):
10179-85.
Stanberry, L. R., A. L. Cunningham, et al. (2000). "Prospects for control of herpes simplex virus disease through immunization." Clin Infect Dis 30(3): 549-66.
Steben, M. (2005). "Genital herpes simplex virus infection." Clin Obstet Gynecol 48(4): 838- 44.
Straus, S. E., A. Wald, et al. (1997). "Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo- controlled vaccine trial." J Infect Dis 176(5): 1129-34.
Strick, L. B., A. Wald, et al. (2006). "Management of herpes simplex virus type 2 infection in HIV type 1-infected persons." Clin Infect Dis 43(3): 347-56.
Takeuchi, O. and S. Akira (2009). "Innate immunity to virus infection." Immunol Rev 227(1):
75-86.
Taylor, T. J., M. A. Brockman, et al. (2002). "Herpes simplex virus." Front Biosci 7: d752-64.
Teuton, J. R. and C. R. Brandt (2007). "Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells." J Virol 81(8): 3731-9.
Turner, R., Z. Shehab, et al. (1982). "Shedding and survival of herpes simplex virus from 'fever blisters'." Pediatrics 70(4): 547-9.
Tyler, K. L. (2004). "Herpes simplex virus infections of the central nervous system:
encephalitis and meningitis, including Mollaret's." Herpes 11 Suppl 2: 57A-64A.
Vannucci, L., F. Chiuppesi, et al. (2010) "Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer." Vet Immunol Immunopathol 134(1- 2): 132-7.
Vollstedt, S., S. Arnold, et al. (2004). "Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1." J Virol 78(8): 3846-50.
Wakim, L. M., C. M. Jones, et al. (2008). "CD8(+) T-cell attenuation of cutaneous herpes simplex virus infection reduces the average viral copy number of the ensuing latent infection." Immunol Cell Biol 86(8): 666-75.
Wald, A. (2004). "Herpes simplex virus type 2 transmission: risk factors and virus shedding."
Herpes 11 Suppl 3: 130A-137A.
Walther, W. and U. Stein (2000). "Viral vectors for gene transfer: a review of their use in the treatment of human diseases." Drugs 60(2): 249-71.
Weidinger, G., M. Ohlmann, et al. (2001). "Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model."
Vaccine 19(20-22): 2764-8.
Weir, J. P., M. Bennett, et al. (1989). "Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge." J Gen Virol 70 ( Pt 10): 2587-94.
Weiss, H. (2004). "Epidemiology of herpes simplex virus type 2 infection in the developing world." Herpes 11 Suppl 1: 24A-35A.
Weitgasser, H. (1977). "[Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G]." Z Hautkr 52(11): 625-8.
Whitley, R. J. and B. Roizman (2001). "Herpes simplex virus infections." Lancet 357(9267):
1513-8.
Whitley, R. J. and B. Roizman (2002). "Herpes simplex viruses: is a vaccine tenable?" J Clin Invest 110(2): 145-51.
Wilson, S. S., E. Fakioglu, et al. (2009). "Novel approaches in fighting herpes simplex virus infections." Expert Rev Anti Infect Ther 7(5): 559-68.
Wiznerowicz, M. and D. Trono (2005). "Harnessing HIV for therapy, basic research and biotechnology." Trends Biotechnol 23(1): 42-7.
Wu, G. A., S. R. Jun, et al. (2009). "Whole-proteome phylogeny of large dsDNA virus families by an alignment-free method." Proc Natl Acad Sci U S A 106(31): 12826-31.
Wu, I. B. and R. A. Schwartz (2007). "Herpetic whitlow." Cutis 79(3): 193-6.
Xu, F., M. R. Sternberg, et al. (2006). "Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States." Jama 296(8): 964-73.
Zabawski, E. J., Jr. (2000). "A review of topical and intralesional cidofovir." Dermatol Online J 6(1): 3.
Zhu, W., C. Guo, et al. (2009). "Microemulsion-based hydrogel formulation of penciclovir for topical delivery." Int J Pharm 378(1-2): 152-8.
Zufferey, R., J. E. Donello, et al. (1999). "Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors." J Virol 73(4): 2886-92.
9 Ringraziamenti
Alla luce del fatto che è la terza tesi che scrivo, dovrei essere ormai un’esperta nel buttare giù i ringraziamenti, invece mi ritrovo a scriverli come ultima cosa; non che sia difficile come fare una tesi, infatti so perfettamente chi ringraziare, ma è difficile piuttosto scriverlo con parole che non siano ovvie o già dette, quindi mi scuso in anticipo per l’eventuale banalità.
Innanzitutto vorrei ringraziare il Prof.Pistello per la fiducia che mi ha dimostrato in tutti questi anni, dalla laurea triennale, alla specialistica e per concludere con il dottorato. Spero che il nostro lavoro insieme possa continuare ancora a lungo.
Vorrei quindi porgere i miei ringraziamenti alle bimbe del Centro Retrovirus, passate, presenti e future (non scordandomi ovviamente dei maschietti Michele e Fulvio) con una particolare riconoscenza ad Anna e Barbara e Fanny che mi hanno fatto compagnia, ed hanno sempre avuto una parola di conforto in questi tempi “bui”.
Un paragrafo a parte se lo sono meritato Laura e Franceschina (e rispettivi fidanZati), che, nonostante mi abbiano abbandonata, continuano a sostenermi anche “a distanza”.
Infine tutta la mia gratitudine va alla mia famiglia, e con famiglia intendo tutti i miei parenti, vicini e lontani, che mi hanno sempre sostenuta ed incoraggiata.
Per concludere, anche se scontato al massimo, vorrei ringraziare Fabio, che mi è stato sempre vicino sin dal liceo, e nonostante questi 11 anni passati insieme, mi fa sentire sempre come se fosse il primo giorno.
Grazie
